Document is current
Any future updates will be listed below
-
Authors
Lee, Jih-Hsiang
Chen, Tom Wei-Wu
Hsu, Chih-Hung
Yen, Yu-Hsin
Yang, James Chih-Hsin
Cheng, Ann-Lii
Sasaki, Shun-ichi
Chiu, LiYin
Sugihara, Masahiro
Ishizuka, Tomoko
Oguma, Toshihiro
Tajima, Naoyuki
Lin, Chia-Chi
-
Funding
Funding for this research was provided by:
Daiichi Sankyo Co., Ltd. (Not applicable)
- License Information
-
More Information
Article History
Received: 15 January 2019
Accepted: 7 February 2019
First Online: 2 March 2019
Compliance with ethical standards
:
: Ann-Lii Cheng has received remuneration as an officer or advisor from Bristol-Myers Squibb, Ono, Bayer, Merck Sharp & Dohme, Novartis, and Eisai Corporation and has received honoraria from Novartis, Eli Lilly, AstraZeneca, and Eisai. Shun-ichi Sasaki, LiYin (Lillian) Chiu, Masahiro Sugihara, Tomoko Ishizuka, Toshihiro Oguma, and Naoyuki Tajima have received remuneration as an officer or advisor from Daiichi Sankyo. The other authors have no conflicts of interest.
: This study was conducted in compliance with the protocol, the ethical principles that have their origin in the Declaration of Helsinki, the ICH consolidated Guideline E6 for GCP (CPMP/ICH/135/95), and applicable local regulatory requirements.
